Abstract

A COMPREHENSIVE REVIEW OF “CONTROLLED RELEASED DRUG DELIVERY SYSTEM FOR THE TREATMENT OF PARKINSON DISEASE”

Isha Kaushal, Anjali Bhagria* and Sanjiv Duggal

ABSTRACT

Drug delivery systems are essential for delivering active pharmaceutical ingredients to achieve therapeutic effects. Traditional methods like tablets, capsules, syrups, and ointments struggle with continuous release due to poor bioavailability and plasma drug levels. To ensure optimal efficacy and safety, controlled drug delivery systems have been developed to administer medication at a precise target spot at a predetermined rate. Over the past 20 years, these systems have advanced from macro and nanoscale to intelligent targeted delivery. Controlled release drug delivery uses drug-encapsulating devices to release therapeutic agents over extended periods at regulated rates. Parkinson's disease (PD) is a common movement disorder caused by striatal dopamine depletion and neurodegeneration. It is primarily caused by environmental and genetic factors. Some medications help PD patients with symptoms, but some have instability and low bioavailability. In Parkinson’s disease, controlled release drug can cross the blood brain barrier to reach the brain and treat the disease. This paper discusses various medications and their potential role in PD treatment and management, and recognizes the work of scientists who have successfully established various Novel drug delivery system (NDDS) approaches for these medications. This study explores controlled-release drug delivery devices for PD, focusing on formulations like polymer-based systems, liposomes, and nanoparticles. These devices aim to reduce adverse effects, increase bioavailability, and maximize medication release. The goal is to create responsive, targeted delivery systems that can adjust to the disease's pathophysiology. This approach has great potential for improving treatment and patient satisfaction in Parkinson's disease.

Keywords: Novel drug delivery system, Parkinson disease.